Assessing the impact and safety of Home IntraVenous Antibiotic Treatment (IVAT) for children with cystic fibrosis

Assessing the impact and safety of home intravenous antibiotic treatment (IVAT) for children with cystic fibrosis: a non-randomised observational study of risk within a therapeutic process

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN65724841

Enrollment

150

Registered

2011-06-28

Start date

2009-03-11

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic fibrosis, respiratory disease Nutritional, Metabolic, Endocrine Cystic fibrosis

Interventions

1. Quantitative inquiry: A within-group prospective study of risk will compare high burden periods, indexed by the delivery of intravenous antibiotic therapy (IVAT) at home with moderate burden when r

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Children aged 13 years or under 2. Confirmed diagnosis of CF for at least one year 3. Caregiver has opted to conduct the IVAT procedure him or herself at home 4. Target gender: male and female

Exclusion criteria

Exclusion criteria: 1. Caregivers administering end-of-life care 2. Profound mental, physical or social problems involving statutory services

Design outcomes

Primary

Measure	Time frame
Adverse event score: untoward occurences during routine T1 and IVAT time T2	—

Secondary

Measure	Time frame
1. Adherence: during routine treatment T1 and IVAT treatment T2 2. Disordered mood (depression and anxiety) in caregivers: Routine treatment T1 and IVAT treatment T2	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026